Trials / Completed
CompletedNCT06184204
Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix®
Prospective, National, Multicentric, Observational Study to Evaluate the Safety, Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® (Rivaroxaban).
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 398 (actual)
- Sponsor
- Beker Laboratories · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The rational behind this observational study is to collect real life data about the use of Trombix® (Rivaroxaban) among patients with atrial fibrillation in Algeria . The aim is to evaluate the safety, efficacy and quality of life.
Detailed description
Trombix® (Rivaroxaban) is used for the treatment of patients with atrial fibrillation. BEKER laboratories are conducting an observation study to evaluate its use among Algerian population in regards to its safety, efficacy and the quality of life of patients after its use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trombix® (Rivaroxaban) | 20mg or 15 mg as per the doctor's prescription |
Timeline
- Start date
- 2023-12-18
- Primary completion
- 2025-03-30
- Completion
- 2025-06-22
- First posted
- 2023-12-28
- Last updated
- 2025-09-19
Locations
17 sites across 1 country: Algeria
Source: ClinicalTrials.gov record NCT06184204. Inclusion in this directory is not an endorsement.